High medication adherence during periconception periods among HIV-1-uninfected women participating in a clinical trial of antiretroviral pre-exposure prophylaxis.
about
Antiretrovirals for primary HIV prevention: the current status of pre- and post-exposure prophylaxisReclaiming fertility awareness methods to inform timed intercourse for HIV serodiscordant couples attempting to conceivePregnancy incidence and outcomes among women receiving preexposure prophylaxis for HIV prevention: a randomized clinical trialTenofovir-based oral preexposure prophylaxis prevents HIV infection among women.Incomplete adherence among treatment-experienced adults on antiretroviral therapy in Tanzania, Uganda and Zambia.PrEP as Peri-conception HIV Prevention for Women and Men.Cost-Effectiveness of Pre-exposure HIV Prophylaxis During Pregnancy and Breastfeeding in Sub-Saharan Africa.Intimate Partner Violence and Adherence to HIV Pre-exposure Prophylaxis (PrEP) in African Women in HIV Serodiscordant Relationships: A Prospective Cohort Study.Values and Preferences on the Use of Oral Pre-exposure Prophylaxis (PrEP) for HIV Prevention Among Multiple Populations: A Systematic Review of the Literature.Emtonjeni-A Structural Intervention to Integrate Sexual and Reproductive Health into Public Sector HIV Care in Cape Town, South Africa: Results of a Phase II Study.Dual contraceptive method use in HIV-serodiscordant Kenyan couples.Acceptability and preferences for safer conception HIV prevention strategies: a qualitative study.Application of an ecological framework to examine barriers to the adoption of safer conception strategies by HIV-affected couples.Fertility desires and preferences for safer conception strategies among people receiving care for HIV at a publicly-funded clinic in Seattle, WA.Tenofovir and tenofovir-diphosphate concentrations during pregnancy among HIV-uninfected women using oral preexposure prophylaxis
P2860
Q28085433-2200BCD0-038D-458B-8AC4-0F1338CD51EDQ34902729-2207C8DE-D3AD-4FF3-BE75-633E7F7A3B34Q35184560-C992A706-3351-490D-AEDB-B1D28B407F87Q36443803-E51D9DB4-BE6A-46C5-9F7E-544CC62A2941Q36506174-FA0FB944-9C70-42FC-BD6E-61C14A838497Q36963511-F5A72F8F-1768-4ED3-ACB0-A0EE96A29BE5Q37298218-0CA961D6-A75F-4724-96A1-1D0B4C7204F0Q37341579-FD0DDF34-518E-45F3-A285-5BC9ED8E02BAQ37736077-0DA208D8-BC58-4D0C-9660-210D21C63546Q40494176-CF01DDC9-E57A-44EC-AF17-5F5C30231166Q40796473-90748E84-4D9A-4ED6-A9AA-0D99FD6DD461Q40992145-C7F5C04C-4B71-454E-8EFB-BDBA84047F3FQ43931427-7C74C772-1ACC-465C-A827-400217235687Q47599389-4F2C659F-2347-42C2-A215-1C9517F6B666Q56910156-FAA3B3A1-59FA-40B9-A32B-A9BDFF00DEAF
P2860
High medication adherence during periconception periods among HIV-1-uninfected women participating in a clinical trial of antiretroviral pre-exposure prophylaxis.
description
2014 nî lūn-bûn
@nan
2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
High medication adherence duri ...... iral pre-exposure prophylaxis.
@ast
High medication adherence duri ...... iral pre-exposure prophylaxis.
@en
High medication adherence duri ...... iral pre-exposure prophylaxis.
@nl
type
label
High medication adherence duri ...... iral pre-exposure prophylaxis.
@ast
High medication adherence duri ...... iral pre-exposure prophylaxis.
@en
High medication adherence duri ...... iral pre-exposure prophylaxis.
@nl
prefLabel
High medication adherence duri ...... iral pre-exposure prophylaxis.
@ast
High medication adherence duri ...... iral pre-exposure prophylaxis.
@en
High medication adherence duri ...... iral pre-exposure prophylaxis.
@nl
P2093
P2860
P50
P1476
High medication adherence duri ...... iral pre-exposure prophylaxis.
@en
P2093
Craig W Hendrix
Jared M Baeten
Lynn T Matthews
Nelly R Mugo
Partners PrEP Study Team
Renee Heffron
P2860
P356
10.1097/QAI.0000000000000246
P407
P577
2014-09-01T00:00:00Z